Compare Fidelity National Information Servcs Inc (FIS) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Zoetis Inc — how do they compare? Fidelity National Information Servcs Inc trades at $34.08 (market cap $17.71B), while Zoetis Inc trades at $74.76 (market cap $30.20B). The key difference: Zoetis Inc is the larger of the two by market cap, and Fidelity National Information Servcs Inc pays the higher dividend (5.13%). Which is the better fit depends on your goals — on Pluang, investors hold Fidelity National Information Servcs Inc for 88 Days and Zoetis Inc for 70 Days on average.
| FIS | ZTS | |
|---|---|---|
Market Cap | $17.71B | $30.20B |
Volume | 9,047,825 | 6,175,327 |
Sector | Technology | Health |
52-Week High | $68.57 | $147.53 |
52-Week Low | $32.44 | $69.09 |
Typical Hold Time | 88 Days | 70 Days |
Enterprise Value | $38.22B | $37.76B |
Dividend Yield | 5.13% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $34.04, up 0.65% on the day, with a bearish technical signal from moving averages and oscillators. The company's valuation metrics appear attractive with a P/E of 5.27 and P/S of 1.46, while recent earnings have shown beats in Q1 and Q2 2026. Revenue is projected to grow to $12.2B in 2026, with net income margin improving to 27.64%. Recent news highlights contract wins and platform modernizations, supporting growth momentum.
The outlook for FIS is cautiously optimistic, with strong analyst support (56.76% buy ratings) and a consensus price target of $47.15 implying significant upside. However, risks include a high debt-to-asset ratio of 39.06% in 2025 and volatile cash flow trends. Investors should weigh the low valuation against execution risks and macroeconomic pressures in the financial technology sector.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
